Clinical Trials Logo

Dry Eye clinical trials

View clinical trials related to Dry Eye.

Filter by:

NCT ID: NCT02161341 Completed - Dry Eye Clinical Trials

Ocular Surface Microbiome in Dry Eye Patients

Start date: June 2014
Phase:
Study type: Observational

The ocular surface is the first line of defence of the eye, it is therefore where external threats are sensed, and potential insults neutralised. Over the course of evolution, various microbes, especially bacteriae, have come to colonise the ocular surface as commensals. The commensals have a role to maintain the homeostasis of the ocular surface. 1 The innate immunity of the ocular surface is very active, and consists of active mechanisms to suppress inflammation 2. For example, there exist macrophages, dendritic cells, suppressor cells, regulatory cells, B cells, IgA, lysozyme, anti-microbial peptides and barriers against external agents. The normal commensals of the ocular surface maintain a basal level of activation of innate defence by stimulating the pattern recognition receptors on ocular surface epithelial cells. This normal composition of microbes is important since inflammation and infection will result if there is introduction of a pathogenic strain that overcomes the flora, or if a dominant strain secretes excessively immunogenic products, such as the exotoxin A of Staphylococcus which triggers marginal keratitis, a form of type IV hypersensitivity. The flora load of microbiome could also influence tear function as a higher flora load was found to be associated with increased mucin degradation 3 and reduced globet cell densitiy 4. Previous studies [I'm not sure which studies these are] at SERI/SNEC also point to the importance of microbes. For example, in dry eye patients, there is increased lysophospholipids in the tear, and this may contribute to inflammatory mediators such as arachidonic acid and other metabolites. The lysophospholipids are formed by phospholipase A2 reactions, and the latter may be microbial in origin. Since dry eye is a known inflammatory disease of the ocular surface, this is one way that microbes can contribute to the pathology.

NCT ID: NCT02160769 Completed - Dry Eye Clinical Trials

Tear Layer Lipid Thickness in Pterygium Patient Before and After Surgery

Start date: November 2013
Phase:
Study type: Observational

The investigators study aims to capture the objective effects of pterygium surgery on tear layer lipid thickness and the tear layer. Previous objective studies of the tear film has been limited to corneal staining grading, tear break up time and Schirmer's test which have been shown to poor to moderate repeatability. The effect of pterygiums on tear layer lipid thickness (LLT) has not previously been explored. With the LipiView Ocular Surface Interferometer, the investigators have the ability to assess the optical coherence interference pattern produced by light reflected off the tear film in a safe and non-invasive manner. Software analysis of the image then measures the tear LLT which can be used to objectively quantify the diagnosis of lipid-deficient dry eye.

NCT ID: NCT02160327 Active, not recruiting - Dry Eye Clinical Trials

The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye

Start date: March 2014
Phase: N/A
Study type: Observational

The specific aims of the the investigators studies are as follows: - To collect the tear samples from patients with different ocular surface disorders, including SLK, conjunctivochalasis, and keratoconjunctivitis sicca (KCS). - To evaluate the differential expression of tear cytokines and pH values between different ocular surface disorders. - To collect the surgical conjunctival specimens from the patients with SLK and conjunctivochalasis. - To evaluate the factors inducing mast cell migration and how mast cell is activated in SLK via surgical specimens and cultivated fibroblast.

NCT ID: NCT02148497 Completed - Healthy Clinical Trials

Multi-Colored Placido Disk Viability

Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to show that the multi-colored Placido Disk set-up can get reliable data over long time periods.

NCT ID: NCT02128763 Completed - Dry Eye Clinical Trials

Dry Eye Assessment and Management Study

DREAM
Start date: November 2014
Phase: Phase 3
Study type: Interventional

The objective of the DREAM study is to evaluate the effectiveness and safety of supplementation with omega-3 fatty acids in relieving the symptoms of moderate to severe dry eye disease.

NCT ID: NCT02116244 Completed - Dry Eye Clinical Trials

Civamide Nasal Solution for the Treatment of Dry Eye

Start date: May 2014
Phase: Phase 2
Study type: Interventional

Keratoconjunctivitis sicca (KCS) or Dry Eye Syndrome is a disease of the surface of the eye, tear film, and related ocular tissues. Millions of people suffer from one form of the disease or another and its prevalence increases with age. Dry Eye Syndrome sufferers experience a broad range of symptoms including discomfort, irritation, burning, itching, redness, pain, gritty feeling, foreign body sensation, blurred vision and ocular fatigue. Civamide is a TRPV-1 receptor modulator that causes the initial stimulation of neuropeptide release and subsequent desensitization to further stimulation of the trigeminovascular system. This provides a pharmacological rational for intranasal route of administration for disorders mediated by the trigeminal nerve or involving the cranial nerve. In nine clinical studies of Civamide Nasal Solution, over 50% of the nearly 300 patients who received Civamide via intranasal administration experienced lacrimation (tearing). This led to the hypothesis that Civamide Nasal Solution might be an appropriate treatment for Dry Eye Syndrome.

NCT ID: NCT02102464 Completed - Dry Eye Clinical Trials

Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers

Start date: April 2014
Phase: N/A
Study type: Interventional

The pilot study objective is to evaluate the potential benefits of LipiFlow® System treatment of contact lens wearers with meibomian gland dysfunction and evaporative dry eye by assessing for improvement in meibomian gland function and reduction of dry eye symptoms in comparison to an untreated control.

NCT ID: NCT02051023 Completed - Dry Eye Clinical Trials

Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)

FML
Start date: February 2014
Phase: Phase 3
Study type: Interventional

Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates the worsening of the disease after exposure to an adverse controlled environment.

NCT ID: NCT02005874 Completed - Dry Eye Clinical Trials

A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition

Start date: November 2013
Phase: N/A
Study type: Observational

The purpose of the study is to collect valuable data on the role of controlled humidity, temperature, airflow, and visual tasking in altering the tear film protein composition. The results from this preliminary study will help to explore the role of tear film markers in inflammatory and disease conditions. This can also be extended to understand the role of the tear film in protecting the ocular surface when individuals are exposed to low humidity environments which may incite discomfort symptoms.

NCT ID: NCT01967147 Completed - Dry Eye Clinical Trials

Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects

Start date: February 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to demonstrate the superior efficacy of Systane® Balance over Preservative-Free 0.9% Saline following 35 days of QID (4 times a day) dosing in treating dry eye subjects with lipid deficiency.